Skip to main content
Delfa

← All assets

Ramelteon

2 trials in this asset. Source: ClinicalTrials.gov, as of July 21, 2026.

Trials

2

Ongoing

0

Recruiting

0

Completed

1

Sites

73

Countries

1

Endpoints

11

Composite endpoints

0

Distinct sites and countries across this asset's trials. A site running several of its trials counts once, matching the map. All 11 linked ClinicalTrials.gov endpoints are classified into the categories below. Trial and endpoint linkage does not by itself establish treatment attribution for every endpoint.

Development

Where the program stands

Trials by phase

Phase 2
1
Not applicable
1

Trials by status

Completed
1
Withdrawn
1

Evidence coverage

What this asset has been measured on

Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.

Behavior / neuropsychiatric
9
Fluid / digital biomarkers
1
Other (unclassified)
1

Most-measured metrics

Top 20 metrics across this asset's endpoints

Normalized metric codes are available for 0 of 11 classified ClinicalTrials.gov endpoints for this asset; the ranking below covers that coded subset.

No normalized metric codes are available for this asset.

Trials

Trials for this asset

Every trial for this asset, with the same search, filters, and sort as the Trials tab.

2 of 2

Alzheimer’s disease and related dementias trials
Asset / Disease areaKey I/E criterionEvidence
NCT00325728Efficacy and Safety of Ramelteon in Subjects With Mild to Moderate Alzheimer's Disease

Ramelteon

Alzheimer’s disease

Alzheimer's diseasePh 2Completed72Aug 20071
NCT00907595Treating Sleep/Wake Cycle Disturbances in Basal Ganglia Disorders With Ramelteon

Ramelteon

Lewy body dementia

Dementia with Lewy bodiesNot applicableWithdrawn1Mar 20103

Showing 1-2 of 2 trials